Dogwood Equity

Dogwood Equity is a private equity firm specializing in buyout, middle market, late-stage growth, and mezzanine investments. It targets small cap companies in the manufacturing, consumer products, distribution, and business services. The firm focuses its investments on smaller metropolitan and non-urban markets in the Southeastern United States, specifically from Maryland to North Florida and east of the Mississippi River. It invests between $1 million and $10 million in equity per transaction. The firm invests in companies with revenues between $5 million and $75 million and EBITDA between $1 million and $10 million. It seeks to make both control and non-control investments. The firm seeks board membership in its portfolio companies. It typically holds its investments for a period of five years. Dogwood Equity was founded in 2002 and is based in Raleigh, North Carolina with an additional office in Charlotte, North Carolina.

Rick Carlisle

Managing Partner

H. Dabney Smith

General Partner

1 past transactions

Biolex Therapeutics

Series D in 2008
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.